Trial Profile
Administration of CIGB-247 in solid malignant tumors. Phase I study on scaling up dosages
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2022
Price :
$35
*
At a glance
- Drugs CIGB 247 (Primary) ; Adjuvants
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms CENTAURO
- 05 Sep 2022 Results from CENTAURO and CENTAURO-2 evaluating potential mechanisms involved in the reduction of platelet-derived free VEGF as a result of vaccination with CIGB-247, published in the Platelets
- 14 Jan 2015 New trial record
- 19 Nov 2014 Results published in the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.